Name | Sulmazole |
Description | Sulmazole (AR-L 115-BS) is a small molecule Sulmazole is a small molecule cGMP-PDE inhibitor.Sulmazole is a competitive inhibitor of A1 adenosine receptors.Sulmazole has been shown to improve cardiac index, low pulmonary capillary wedge pressure, and can be used in the study of heart failure.Sulmazole is a small molecule cGMP-PDE inhibitor. |
In vitro | In cell-free biochemical assays, observed activities of sulmazole are cyclic nucleotide phosphodiesterase inhibitors with similar potencies and selectivities for the Type III enzyme (IC50=5.0 +/- 1.9 X 10(-5) M). sulmazole had little or no effects on sarcolemmal Na+/K+-ATPase, Ca2+ ATPase or Na+/Ca2+ exchange, and sulmazole had a small, stimulatory effect on myofibrillar ATPase.[2] |
In vivo | In anaesthetized guinea pigs and dogs, bolus i.v. injections of sulmazole (0.1-10.0 mg kg-1) caused a significant, dose-related increase in ventricular dP/dt, and a reduction in diastolic blood pressure, with small increases in heart rate.[1] |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 6.25 mg/mL (21.75 mM), Sonication is recommended.
|
Keywords | Sulmazole |
Inhibitors Related | Kaempferol | Hydroxychloroquine | Metronidazole | Nitazoxanide | Doxycycline | Benzyl benzoate | Theobromine | Doxofylline |
Related Compound Libraries | Anti-Parasitic Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Inhibitor Library | Bioactive Compounds Library Max | GPCR Compound Library |